Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aims of the investigators' study are to investigate the effect of H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.
Accumulating evidence shows that Helicobacter pylori protects against some metabolic and immunological diseases in which the development of these diseases coincide with temporal or permanent dysbiosis. Helicobacter pylori eradication therapy has the potential to improve symptoms of functional dyspepsia. The aims of our study are to investigate the effect of H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HP eradication group | Experimental | HP eradication group Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days | Drug | Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change of gut microbiome | Change of gut microbiome at 3 months, and 6 months regardless of Helicobater positive or negative | at 3 months, and 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Symptom of dyspepsia | Improvement of NDI-K, HADS,SEQ-FD at 3 and 6 months | at 3 months, and 6 months |
| Eradication of helicobacter pylori | Eradication rate of helicobacter pylori at 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kee Wook Jung, MD, PhD | Contact | 821026778856 | jung.keewook30@gmail.com | |
| Ga Hee Kim, MD, PhD | Contact | 821028732884 | smallgh@hanmail.net |
| Name | Affiliation | Role |
|---|---|---|
| Kee Wook Jung, MD, PhD | Asan Medical Center | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D004415 | Dyspepsia |
| ID | Term |
|---|---|
| D012817 | Signs and Symptoms, Digestive |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C000631239 | tegoprazan |
| C494814 | BID protein, human |
| D000658 | Amoxicillin |
| D017291 | Clarithromycin |
| ID | Term |
|---|---|
| D000667 | Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D047090 | beta-Lactams |
| D007769 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| at 3 months |
| Histologic finding of UGI tract | Change of accumulationof inflammatory cells, eosinophils of esophagus, stomachm duodenal mucosal biopsy | at initial and 3 months |
| Lactams |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D004917 | Erythromycin |
| D018942 | Macrolides |
| D061065 | Polyketides |
| D007783 | Lactones |